Alprostadil (Vitaros), the first cream to treat men with erectile dysfunction, is now available for prescription in the UK.
The new topical cream comes in a single use, disposable applicator that is easy to use and suitable for many of the 2.3 million men with ED in the UK. It provides healthcare professionals with an alternative, non-invasive option for those men considering alprostadil treatment. After applying the pre-measured amount of cream (100μl) to the tip of the penis, the new skin permeation technology within the cream (NexACT®-DDAIP) results in the rapid absorption of alprostadil by loosening the epidermal tight junctions, producing an erection within 5-30 minutes. Men in the UK will be the first in the world to have access to this new treatment for ED.
No one single treatment is suitable for all men with ED meaning many men miss out on the chance for
treatment. For example, some men cannot tolerate oral treatments due to systemic side effects, such as
headache and dizziness, or cannot take them because they are contraindicated. As men with ED tend to be
taking numerous medications for underlying medical conditions, some simply do not want to take another
oral treatment. Many men are also put off by the existing administration methods for alprostadil, such as an
injection into the penis or a pellet inserted into the urethra.
Professor Raj Persad, Consultant Urologist and Andrologist, The Bristol Urological Institute said; "Vitaros is
an important step forward in the treatment of ED, particularly for those men where we struggle to find an
appropriate treatment. It offers men an alternative option that acts locally and has non-invasive
administration, meaning more men can potentially receive treatment for their ED. Current alprostadils are normally prescribed in secondary care because of the way they are administered. As Vitaros is easy to use and only needs verbal instruction around the application of the cream, it could potentially be prescribed in primary care, giving GPs and practice nurses the ability to treat more men with ED."
It is important that men suffering with erection problems go to see a healthcare professional as ED can be an early warning sign for serious conditions such as cardiovascular disease, indicating that a man could be at risk of angina or a heart attack within the next 3-5 years. This could occur even in men in their early fourties.
In the 12-week phase III placebo-controlled clinical trials (n=1732), almost 40% of men using 300mcg of topical alprostadil experienced a clinically significant improvement in their erection function (IIEF-EF), compared to 21% of men using placebo (p<0.0001). Over half of men were satisfied with their erection (measured by the Global Assessment Questionnaire (GAQ)) after using 300mcg of topical alprostadil, compared to only 20% of men using placebo (p<0.0001). In particular, more men with a variety of conditions such as diabetes, high blood pressure and cardiac disease (53% (n=42), 49% (n=91) and 50% (n=63) respectively), were satisfied with their erection after using 300mcg of topical alprostadil, compared to those using placebo (20% (n=15), 20% (n=35) and 17% (n=19) respectively).
In the long-term open label study, the majority (90%) of men using 300mcg of topical alprostadil for six months considered their erection improved compared to their erection at the beginning of the trial (measured by GAQ).
All common observed side effects of Vitaros® treatment are localised to the application site and are generally mild and of short duration. Prolonged erections lasting more than four hours (priapism) were observed rarely. If priapism occurs, the man should seek immediate medical assistance.
Related Stories: Men's health forum relaunch Man MOT service